(Q33960392)

30 July 2017

1 reference

title

Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works (English)

1 reference

30 July 2017

0 references

Amélia Mendes

1

1 reference

PubMed ID

21755136

30 July 2017

Maria José Sá

series ordinal

2

1 reference

30 July 2017

1 June 2011

1 reference

Arquivos de Neuro-Psiquiatria

30 July 2017

1 reference

30 July 2017

69

1 reference

30 July 2017

3

1 reference

30 July 2017

536-543

1 reference

Multiple sclerosis: risk factors, prodromes, and potential causal pathways

30 July 2017

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Interferon-beta: mechanism of action and dosing issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Interferon-beta mechanisms of action in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Th17 Cells and autoimmune encephalomyelitis (EAE/MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Glatiramer acetate: mechanisms of action in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2011000400024

10.1590/S0004-282X2011000400024

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

21755136